Quantum chemical (QM:MM) investigation of the mechanism of enzymatic reaction of tryptamine and N,N-dimethyltryptamine with monoamine oxidase A.
Organic & Biomolecular Chemistry November 20, 2020 DOI: 10.1039/d0ob01118e (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In silico study Peer reviewed |
|---|---|
| Topics | 5-MeO-DMT DMT |
| Citations | 12 |
| Key points | Oxidation of the tertiary amine DMT requires a lower activation barrier than the primary amine tryptamine, and at pH 7.4 the protonated substrates enter the enzyme, with FADH+ yielding lower activation barriers than FAD. |
Abstract
The endogenous psychedelic (mind-altering) N,N-dimethyltryptamine (DMT) molecule has an important role in tissue protection, regeneration, and immunity via sigma-1 receptor activation as its natural ligand. The immunologic properties of DMT suggest this biogenic compound should be investigated thoroughly in other aspects as well. In our in silico project, we examined the metabolism of DMT and its primary analogue, the tryptamine (T), by the monoamine oxidase (MAO) flavoenzyme. MAO has two isoforms, MAO-A and MAO-B. MAOs perform the oxidation of various monoamines by their flavin adenine dinucleotide (FAD) cofactor. Two-layer QM:MM calculations at the ONIOM(M06-2X/6-31++G(d,p):UFF=QEq) level were performed including the whole enzyme to explore the potential energy surface (PES) of the reactions. Our findings reinforced that a hybrid mechanism, a mixture of pure H+ and H- transfer pathways, describes precisely the rate-determining step of amine oxidation as suggested by earlier works. Additionally, our results show that the oxidation of tertiary amine DMT requires a lower activation barrier than the primary amine T. This may reflect a general rule, thus we recommend further investigations. Furthermore, we demonstrated that at pH 7.4 the protonated form of these substrates enter the enzyme. As the deprotonation of substrates is crucial, we presumed protonated cofactor, FADH+, may form. Surprisingly, the activation barriers are much lower compared to FAD with both substrates. Therefore, we suggest further investigations in this direction.
Citations in the library
Cited by 5
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025
- A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach. Biochemical and Biophysical Research Communications October 20, 2023
- Exploring Endogenous Tryptamines: Overlooked Agents Against Fibrosis in Chronic Disease? A Narrative Review Livers December 27, 2024
- A theoretical investigation of DMT metabolism and the formation of apotential biomarker
- Quantum Chemical Study of the Hydrolysis of Oxidized Endogenous Psychedelic N,N-Dimethyltryptamine
Cites 23
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the Catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor Molecular Pharmacology December 1, 2001
- Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports October 13, 2017
- Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of Ayahuasca Journal of Ethnopharmacology April 1, 1984
- Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Therapeutic Advances in Psychopharmacology March 18, 2016
and 18 more in the library